Coronavirus Disease 2019 (COVID-19) Severity Among Women of Reproductive Age With Symptomatic Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Pregnancy Status-United States, 1 January 2020-25 December 2021.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
03 10 2022
Historique:
pubmed: 20 6 2022
medline: 6 10 2022
entrez: 19 6 2022
Statut: ppublish

Résumé

Information on the severity of coronavirus disease 2019 (COVID-19) attributable to the Delta variant in the United States among pregnant people is limited. We assessed the risk for severe COVID-19 by pregnancy status in the period of Delta variant predominance compared with the pre-Delta period. Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among symptomatic women of reproductive age (WRA) were assessed. We calculated adjusted risk ratios for severe disease including intensive care unit (ICU) admission, receipt of invasive ventilation or extracorporeal membrane oxygenation (ECMO), and death comparing the pre-Delta period (1 January 2020-26 June 2021) and the Delta period (27 June 2021-25 December 2021) for pregnant and nonpregnant WRA. Compared with the pre-Delta period, the risk of ICU admission during the Delta period was 41% higher (adjusted risk ratio [aRR], 1.41 [95% confidence interval {CI}, 1.17-1.69]) for pregnant WRA and 9% higher (aRR, 1.09 [95% CI, 1.00-1.18]) for nonpregnant WRA. The risk of invasive ventilation or ECMO was higher for pregnant (aRR, 1.83 [95% CI, 1.26-2.65]) and nonpregnant (aRR, 1.34 [95% CI, 1.17-1.54]) WRA in the Delta period. During the Delta period, the risk of death was 3.33 (95% CI, 2.48-4.46) times the risk in the pre-Delta period among pregnant WRA and 1.62 (95% CI, 1.49-1.77) among nonpregnant WRA. Compared with the pre-Delta period, pregnant and nonpregnant WRA were at increased risk for severe COVID-19 in the Delta period.

Sections du résumé

BACKGROUND
Information on the severity of coronavirus disease 2019 (COVID-19) attributable to the Delta variant in the United States among pregnant people is limited. We assessed the risk for severe COVID-19 by pregnancy status in the period of Delta variant predominance compared with the pre-Delta period.
METHODS
Laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among symptomatic women of reproductive age (WRA) were assessed. We calculated adjusted risk ratios for severe disease including intensive care unit (ICU) admission, receipt of invasive ventilation or extracorporeal membrane oxygenation (ECMO), and death comparing the pre-Delta period (1 January 2020-26 June 2021) and the Delta period (27 June 2021-25 December 2021) for pregnant and nonpregnant WRA.
RESULTS
Compared with the pre-Delta period, the risk of ICU admission during the Delta period was 41% higher (adjusted risk ratio [aRR], 1.41 [95% confidence interval {CI}, 1.17-1.69]) for pregnant WRA and 9% higher (aRR, 1.09 [95% CI, 1.00-1.18]) for nonpregnant WRA. The risk of invasive ventilation or ECMO was higher for pregnant (aRR, 1.83 [95% CI, 1.26-2.65]) and nonpregnant (aRR, 1.34 [95% CI, 1.17-1.54]) WRA in the Delta period. During the Delta period, the risk of death was 3.33 (95% CI, 2.48-4.46) times the risk in the pre-Delta period among pregnant WRA and 1.62 (95% CI, 1.49-1.77) among nonpregnant WRA.
CONCLUSIONS
Compared with the pre-Delta period, pregnant and nonpregnant WRA were at increased risk for severe COVID-19 in the Delta period.

Identifiants

pubmed: 35717652
pii: 6611488
doi: 10.1093/cid/ciac479
pmc: PMC9214133
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S317-S325

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Déclaration de conflit d'intérêts

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Auteurs

Penelope Strid (P)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lauren B Zapata (LB)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Van T Tong (VT)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Laura D Zambrano (LD)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kate R Woodworth (KR)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Aspen P Riser (AP)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Romeo R Galang (RR)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Suzanne M Gilboa (SM)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sascha R Ellington (SR)

Epidemiology Task Force, Pregnancy and Infant Linked Outcomes Team, COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH